Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal AdenocarcinomaGlobeNewsWire · Sep 9, 2026
Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid TumorsGlobeNewsWire · Aug 26, 2026
Radiopharm Theranostics (NASDAQ:RADX) Trading Down 8.4% – What’s Next?Defense World · Aug 21, 2026
Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical TrialGlobeNewsWire · Aug 20, 2026Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers).
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 28, 2026 | -$1.67 | -$1.20 | Beat |
| Feb 27, 2026 | -$1.51 | -$2.25 | Miss |
| Aug 29, 2025 | -$1.58 | -$1.78 | Miss |
| Feb 28, 2025 | -$1.49 | -$1.91 | Miss |
| Feb 29, 2024 | – | -$14.10 | |
| Feb 28, 2023 | – | -$8.71 |